Endonovo Therapeutics (ENDV) Other Non-Current Liabilities (2016 - 2023)
Endonovo Therapeutics has reported Other Non-Current Liabilities over the past 8 years, most recently at $5.9 million for Q3 2023.
- Quarterly results put Other Non-Current Liabilities at $5.9 million for Q3 2023, up 7294.71% from a year ago — trailing twelve months through Sep 2023 was $5.9 million (up 7294.71% YoY), and the annual figure for FY2022 was $79825.0, changed 0.0%.
- Other Non-Current Liabilities for Q3 2023 was $5.9 million at Endonovo Therapeutics, up from $79825.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ENDV hit a ceiling of $10.6 million in Q4 2019 and a floor of $79825.0 in Q4 2021.
- Median Other Non-Current Liabilities over the past 5 years was $5.0 million (2022), compared with a mean of $4.4 million.
- Biggest five-year swings in Other Non-Current Liabilities: crashed 98.76% in 2022 and later skyrocketed 7294.71% in 2023.
- Endonovo Therapeutics' Other Non-Current Liabilities stood at $10.6 million in 2019, then tumbled by 98.54% to $155000.0 in 2020, then plummeted by 48.5% to $79825.0 in 2021, then changed by 0.0% to $79825.0 in 2022, then skyrocketed by 7294.71% to $5.9 million in 2023.
- The last three reported values for Other Non-Current Liabilities were $5.9 million (Q3 2023), $79825.0 (Q2 2023), and $9.3 million (Q1 2023) per Business Quant data.